Tag: daewoong pharmaceutical

daewoong pharmaceutical

Latest News

미국 ITC 위원회는 16일(현지시간) 대웅제약의 보툴리눔 톡신 제제 '나보타'(미국 제품명 주보)가 불공정 무역관행 제재 규정을 위반한 제품이라 판단해 21개월간 미국 내 수입 금지를 명령하는 최종판결을 내렸다. 지난해 1월 보툴리눔 톡신 제제 '메디톡신'의 제조사 메디톡스는 대웅제약이 자사의 균주와 제조공정 기술문서 등을 훔쳐 갔다고 보고 ITC에 영업비밀 침해 혐의로 공식 제소했다. 사진은 17일 서울 강남구에 위치한 메디톡스 빌딩과 대웅제약 본사의 모습. 2020.12.17 ondol@yna.co.kr/2020-12-17 15:22:59/

Medytox-Daewoong Botox feud flares anew with 10-fold damages claim

Medytox has raised its damages claim tenfold against Daewoong Pharmaceutical as their nine-year dispute over botulinum toxin technology continues in Korean courts.

2026.9.7

Kim Do-young, head of Daewoong Pharmaceutical’s Global Development Center, poses for a photo on Wednesday during the CPHI Worldwide 2023 held in Barcelona. [DAEWOONG PHARMACEUTICAL]

Daewoong sets $745 million sales target for duo of new drugs

BARCELONA, Spain — Daewoong Pharmaceutical hopes to achieve $745 million in global sales with its new drugs Fexuclue, a gastroesophageal reflux medication, and Envlo, a diabetes treatment, by 2030.

2023.10.26

Most popular

Samsung Biologics' exhibition booth at CPHI Worldwide 2023 held in Barcelona, Spain [SAMSUNG BIOLOGICS]

CPHI Worldwide begins in Barcelona with Korean heavyweights

CPHI Worldwide, the largest pharmaceutical trade show, started in Barcelona with major Korean biopharma players in attendance. Over 2,500 companies from 170 countries are exhibiting.

2023.10.24

Daewoong begins sales of Nuceiva botulinum in Italy

Daewoong Pharmaceutical began sales of its Nabota botulinum toxin in Italy, the Korean pharmaceutical company said Friday.

2023.6.30

Daewoong Pharmaceutical's headquarters in Gangnam, southern Seoul [DAEWOONG PHARMACEUTICAL]

Enavogliflozin Phase 3 trials to begin in China

Daewoong Pharmaceutical won approval to start Phase 3 clinical trials of Enavogliflozin, a diabetes treatment, from regulators in China.

2022.2.22

The AllCheck Covid-19 test kit [DAEWOONG PHARMACEUTICAL]

Daewoong Pharmaceutical signs Covid test kit deal in Vietnam

Daewoong Pharmaceutical said Monday it will supply Vietnamese pharmaceutical company Vietha Pharma Covid-19 diagnostic kits in a deal potentially worth 12 billion won ($10.2 million).

2021.11.15

Daewoong Pharmaceutical’s headquarters in Hwaseong, Gyeonggi [DAEWOONG PHARMACEUTICAL]

Daewoong Pharmaceutical signs Fexuprazan deal in Middle East

Daewoong Pharmaceutical signed a deal potentially worth 99.1 billion won ($83.7 million) with Aghrass Healthcare Limited to license its Fexuprazan gastroesophageal reflux treatment.

2021.10.15

Phase 1 trials to begin on Daewoong's IVL3001 hair loss treatment

Daewoong Pharmaceutical won approval in Australia for Phase 1 clinical trials of the IVL3001 hair loss treatment, the company said Monday.

2021.9.27

Daewoong Pharmaceutical's Nabota. [DAEWOONG PHARMACEUTICAL]

Nabota Phase 3 trials in China achieve meaningful results

Daewoong Pharmaceutical said Wednesday its Nabota botulinum toxin demonstrated statistically meaningful results in Phase 3 trials in China, signaling an imminent entry to the market, the second largest botulinum toxin market in the world.

2021.7.28

Medytox, Daewoong benefit as Botox deal nullifies ITC ban

After emerging victorious in a protracted trade secrets dispute last year, Medytox has received billions of dollars in license fees and royalty fees and bought a stake in the U.S. botulinum toxin maker Evolus, becoming its second largest stakeholder.

2021.2.22